Hong Kong has approved emergency use of an mRNA vaccine co-developed by German drug company BioNTech and Chinese Fosun Pharma. The two companies have committed to supply at least 100 million doses to China in 2021. CGTN's Wu Lei talked to BioNTech CEO Ugur Sahin to see whether such a large number of vaccines can be delivered on time？
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3